PHARMADRUG COMMENCES TRADING ON THE OTCQB MARKET IN THE UNITED STATES
Pharmadrug Inc. has qualified for trading on the OTCQB Venture Market operated by the OTC Markets Group Inc. The company's common shares commenced trading yesterday on the OTCQB under the symbol LMLLF. The company's common shares will continue to trade on the Canadian Securities Exchange under the symbol PHRX.
Daniel Cohen, chief executive officer of Pharmadrug, commented: "We are extremely excited to be posting our shares on the OTCQB, a well-known U.S. Securities platform. We believe the strategy to increase U.S. investor ownership fits well with the growing focus on biotech research and development as well as the company's intention to both lead and collaborate on several FDA clinical trials."
About Pharmadrug Inc.
Pharmadrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally derived approved drugs. The company owns 100 per cent of Pharmadrug Production GmbH, a German medical cannabis distributor, with a Schedule I European Union narcotics licence and German EuGMP certification allowing for the importation and distribution of medical cannabis to pharmacies in Germany and throughout the European Union. Pharmadrug recently acquired Sairiyo Therapeutics, a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the United States and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of COVID-19 and rare cancers. Sairiyo is also conducting research and development in the psychedelics space for the treatment of non-neuropsychiatric conditions. The company also owns 100 per cent of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms and psilocybin mushrooms, where federally legal, as natural-based medicines.